|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2007-11-2
|
|
pubmed:abstractText |
Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) are used to determine human epidermal growth factor receptor-2 (HER-2) status and patient eligibility for trastuzumab therapy. Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AntoineMartineM,
pubmed-author:ArnouldLaurentL,
pubmed-author:ArveuxPatrickP,
pubmed-author:CoudertBruno PBP,
pubmed-author:CouturierJeromeJ,
pubmed-author:EttoreFrancetteF,
pubmed-author:FumoleauPierreP,
pubmed-author:Gelly-MartyMarionM,
pubmed-author:LoustalotCatherineC,
pubmed-author:Penault-LlorcaFrederiqueF,
pubmed-author:SaganChristineC,
pubmed-author:VasseurBerangereB
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6404-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17975153-Adult,
pubmed-meshheading:17975153-Aged,
pubmed-meshheading:17975153-Antibodies, Monoclonal,
pubmed-meshheading:17975153-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17975153-Antineoplastic Agents,
pubmed-meshheading:17975153-Biopsy,
pubmed-meshheading:17975153-Breast Neoplasms,
pubmed-meshheading:17975153-Female,
pubmed-meshheading:17975153-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17975153-Humans,
pubmed-meshheading:17975153-Immunohistochemistry,
pubmed-meshheading:17975153-In Situ Hybridization, Fluorescence,
pubmed-meshheading:17975153-Middle Aged,
pubmed-meshheading:17975153-Neoadjuvant Therapy,
pubmed-meshheading:17975153-Neoplasms,
pubmed-meshheading:17975153-Receptor, erbB-2,
pubmed-meshheading:17975153-Retrospective Studies,
pubmed-meshheading:17975153-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
|
|
pubmed:affiliation |
CLCC G-F Leclerc and 1FR100, Dijon, France. larnould@dijon.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article
|
